Gilead nabs 'breakthrough' tag for hep C combo; IMS Health, investors snag $1.3B in IPO

@FiercePharma: Top-read story this weekend: Novartis fighting two-pronged legal battle in India on Galvus patent. Story | Follow @FiercePharma

@TracyStaton: FiercePharma's best-read marketing story: Sanofi aims for outcomes with new Chief Patient Officer. Article | Follow @TracyStaton

@EricPFierce: Daiichi Sankyo hinted months ago it was tired of Ranbaxy's issues. Buyout means Sun Pharma takes them on. More | Follow @EricPFierce

@CarlyHFierce: Novartis meningitis B vaccine Bexsero receives FDA breakthrough therapy designation in the U.S. Release | Follow @CarlyHFierce

> Gilead Sciences ($GILD) won a "breakthrough" designation from the FDA for its hepatitis C combo pill, putting it in line for U.S. approval by October 10. Report

> IMS Health Holdings ($IMS) priced its initial public offering at $20 per share to raise $1.3 billion. Report (sub. req.)

> Roche ($RHHBY) snapped up a medical testing equipment maker, IQuum, for up to $450 million. Report

> GlaxoSmithKline's ($GSK) Asia unit pulled its over-the-counter painkiller Crocin Advance after Indian officials ordered it to stop selling the drug because it was overcharging for it. Report

> Specialty pharmacy Diplomat signed up with Celgene ($CELG) to distribute the company's brand new psoriatic arthritis treatment Otezla in the U.S. Report

> A U.S. judge sentenced a South Florida "pill mill" doctor to more than 6 years in prison for money-laundering, in a case related to thousands of painkiller prescriptions she wrote. Report

Medical Device News

@FierceMedDev: CyVek immunoassay technology gets $10M investment. Story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: After a successful IPO, LDR looks to raise more cash. News | Follow @VarunSaxena2

@MichaelGFierce: DNA nanorobot delivers drugs through flap that opens and closes. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Motorized, sensor-driven wheelchair could provide a new level of mobility for those with severe disabilities. Article | Follow @EmilyWFierce

> Edwards Lifesciences wins CE mark for aortic valve system. More

> Roche snags diagnostics outfit IQuum in $450M deal. Story

> Medtronic buys out a distributor as it cozies up to Turkey. News

Biotech News

@FierceBiotech: Little Deciphera raises its cancer R&D flag in Boston's bustling biotech hub. More | Follow @FierceBiotech

@JohnCFierce: Agios shares spike on enthusiastic response to small, early-stage leukemia study. Story | Follow @JohnCFierce

@DamianFierce: Here's FierceBiotech's look at every drug developer IPO from the first quarter. Report | Follow @DamianFierce

@EmilyMFierce: 40% of the world's population is at risk from dengue. More in WHO's report for World Health Day. Report | Follow @EmilyMFierce

CRO News

> Clinipace signs up to get a brain-stimulating device on the U.S. market. Article

> WuXi bets on anti-counterfeiting tech with an eye on drug safety. More

> Actavis picks Particle Sciences for generics development. Story

> AMRI expects its $41M Cedarburg deal to pay off right away. News

> Evotec lands two more deals to share risks and rewards of R&D. Report

> Charles River wraps up $179M deal for Galapagos' CRO biz. Item

Biotech IT News

> Merck KGaA and Pfizer tap into Broad Institute's data skills for lupus project. Story

> Tufts survey shows social media still on fringes of clinical trials. More

> Billionaire-backed startup puts Big Data, AI at the heart of drug discovery. News

> Merck vaccine plant taps R&D's Big Data platform to solve yield conundrum. Article

> IMS Health stock jumps after second biggest U.S. IPO of 2014. Item

> Europe to create public clinical trial results database after passing law. Report

And Finally... Most states are secretive about their execution drugs, a policy that's under increasing legal attack. Report

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.